Teachers Retirement System of The State of Kentucky Reduces Holdings in Moderna, Inc. (NASDAQ:MRNA)

Teachers Retirement System of The State of Kentucky decreased its stake in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 36.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 183,640 shares of the company's stock after selling 104,247 shares during the period. Teachers Retirement System of The State of Kentucky's holdings in Moderna were worth $7,637,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in the stock. Norges Bank bought a new stake in Moderna in the 4th quarter worth $163,833,000. FMR LLC boosted its holdings in shares of Moderna by 7.4% during the fourth quarter. FMR LLC now owns 18,664,634 shares of the company's stock worth $776,075,000 after purchasing an additional 1,282,469 shares during the period. Pictet Asset Management Holding SA grew its stake in shares of Moderna by 170.5% in the fourth quarter. Pictet Asset Management Holding SA now owns 1,766,398 shares of the company's stock worth $73,447,000 after purchasing an additional 1,113,455 shares during the last quarter. Invesco Ltd. increased its holdings in Moderna by 24.3% during the 4th quarter. Invesco Ltd. now owns 5,006,462 shares of the company's stock valued at $208,169,000 after purchasing an additional 979,858 shares during the period. Finally, Renaissance Technologies LLC raised its position in Moderna by 225.7% during the 4th quarter. Renaissance Technologies LLC now owns 1,010,758 shares of the company's stock valued at $42,027,000 after purchasing an additional 700,458 shares during the last quarter. Hedge funds and other institutional investors own 75.33% of the company's stock.

Analyst Ratings Changes

Several equities analysts have recently issued reports on MRNA shares. Royal Bank of Canada reissued a "sector perform" rating and set a $40.00 target price on shares of Moderna in a research note on Tuesday, February 18th. Morgan Stanley decreased their target price on Moderna from $39.00 to $32.00 and set an "equal weight" rating for the company in a research report on Wednesday, April 9th. Barclays lowered Moderna from an "overweight" rating to an "equal weight" rating and dropped their price target for the company from $111.00 to $45.00 in a research report on Tuesday, February 18th. William Blair reiterated a "market perform" rating on shares of Moderna in a report on Thursday, April 17th. Finally, Evercore ISI set a $50.00 target price on shares of Moderna in a report on Friday, February 14th. Four research analysts have rated the stock with a sell rating, sixteen have given a hold rating, three have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company has an average rating of "Hold" and a consensus price target of $58.70.

Moderna Trading Down 0.6 %

NASDAQ:MRNA traded down $0.17 during trading hours on Friday, reaching $27.22. The company had a trading volume of 7,714,270 shares, compared to its average volume of 7,325,199. The firm's 50 day moving average price is $30.36 and its 200-day moving average price is $38.85. The firm has a market cap of $10.52 billion, a price-to-earnings ratio of -2.93 and a beta of 2.23. Moderna, Inc. has a 52 week low of $23.15 and a 52 week high of $170.47.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.